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Summary 
Regional rat brain uptake of [18F]GBR 13119, a high specific activity, 
positron-emitter labeled derivative of the potent dopamine uptake 
antaqonist GBR 12935, is reported. Striat~n to cerebellum ratios of 3 
are obtained at 90 minutes post injection. Specific binding in stri- 
atum can be blocked by pretreatment with dopamine uptake system an- 
tagonists (mazindol, nomifensine) but not with receptor antagonists 
(spiperone, flupenthixol). [18F]GBR 13119 is proposed as a new posi- 
tron-emitting radioligand for in vivo PET studies of the pre-synaptic 
dopamine uptake system. 
Dysfunctions of the brain dopaminergic system have been demonstrated as 
the underlying biochemical change in certain neurological diseases (Parkinson's 
disease) (i) and have been implicated in psychiatric disorders (schizophrenia) 
(2). The study of the dopamine system in vivo using Positron Emission Tomo- 
graphv (PET) has been vigorously pursued. Most PET studies of dopamine receptor 
pharmacology have centered on measurements of the number (Bmax) and affinity 
(Kd) of post-synaptic receptors (or some combination of these terms) using 
carbon-ll, fluorine-18 or bromine-75 labeled neuroleptics (e.g., spiperone) or 
benzamides (e.g., raclopride) for D 2 receptors, and benzazepines (e.g., SCH 
23390) for D 1 receptors (3,4). Determination of DOPA uptake and in vivo meta- 
bolism to dopamine has been approached using [I-IIc]DOPA and 6-[18F]fluoroDOPA. 
Promising results in PET studies of Parkinson's patients (5), MPTP-poisoned 
individuals (6), and schizophrenics (7) have been reported using these various 
radiopharmaceuticals. 
A third component of the dopaminergic system is the pre-synaptic dopamine 
uptake system, which is important in the regulation of dopamine concentration 
in the synapse. Numerous compounds have been reported as antagonists of the 
uptake system, among them nomifensine, mazindol, methylphenidate, and GBR 12935: 
labeling of such ligands with carbon-ll or fluorine-18 would produce potential 
in vivo markers of dopaminergic neuronal density. Nomifensine has been recently 
reported in carbon-ll labeled form; in vivo studies have been described as 
promising but evaluation remains incomplete (8). Reported here is the regional 
in vivo brain uptake of [18F]GBR 13119 ((l-[4-[18F]fluorophenyl)phenylmethoxy] 
ethyl-4-(3-phenylpropyl)piperazine, Figure i), a fluorine-18 labeled derivative 
of the potent and selective dopamine uptake antagonist GBR 12935. The results 
are also compared to recently reported in vivo data obtained with the structur- 
ally similar dopamine uptake antagonist [3H]GBR 12783. 
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FIG 1. 
Chemical structures of [18F]GBR 13119 (R=I8F) and GBR 12935 (R=H). 
Materials and Methods 
Chemicals 
[18F]GBR 13119 was prepared in high radiochemical purity (> 99%) and high 
specific activity (> i000 Ci/mmol) by a four-step synthesis reported elsewhere 
(9). Mazindol was obtained from Sandoz Pharmaceuticals, and nomifensine from 
Hoechst-Roussel. 
Animal Studies 
Sprague-Dawley rats (150-200 g) were anesthesized and injected with 
[18F]GBR 13119 (10-600 ~Ci) in saline - 5% ethanol, via Me surgically exposed 
femoral vein. At designated times animals were sacrificed by decapitation and 
the brain rapidly dissected i0). Tissue samples were weighed, then counted in 
an automatic gamma counter. 
For blocking studies animals were injected, 30 minutes prior to radiotracer 
injection, with appropriate amounts of competing ligand dissolved in dilute 
acetic acid - saline solution. Control animals were injected with vehicle 
alone. Data were analyzed for statistical analysis using a two-tailed st~ent's 
t-test: p values are given in the Tables. 
Results 
The time course of [18F]GBR 13119 uptake and retention in various brain 
regions (striat~, cortex and cerebellum) is shown in Table I. Uptake of 
radiotracer is rapid, with 0.608% of the injected dose in the brain at 2 minutes. 
Whole brain radioactivity decreases thereafter. Radioactivity is well retained 
in striat~, and the striat~ to cerebell~ ratio (target to nontarget ratio) 
increases to 3 at 90 minutes post injection. 
Pharmacological blocking studies of [18F]GBR 13119 are shown in Tables II 
and III. Pretrea~ent with 8 mg/kg mazindol or nomifensine, compounds which 
inhibit monoamine uptake (incl~ing dopamine), completely blocks selectivity in 
retention of [18F]GBR 13119 in striatum, with striatum-to-cerebellum ratios 
reduced to one. Pretrea~ent with the dopamine receptor antagonists spiperone 
(D 2 receptors) or cis-flupenthixol (D 1 receptors) has no effect on either 
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TABLE II[* 
300 ug/kg 300 ug/kg 
control flupenthixol spiperone 
time 60 min 60 min 
% ID/g 
s t r i a t ~  0,294 + .064 0.361 + .009 0,27? + .010 
cortex 0.187 + .035 0.190 + .010 0.172 + .050 
cerebellum 0.132 + .031 0.138 + .006 0.141 + .031 
blood 0.035 + .0036 0.059 + .006 0.038 + .012 
striatum 
cerebellum 2.58 + .95 2.58 + .007** 1.91 + .330** 
*Pretreatment 30 minutes before radiotracer injection. 
4-10 animals per data point. 
**p > 0.12 
Effects of Dopamine Receptor Antagonists on [18F]GBR 13119 
Uptake In Vivo in Rat Brain 
Discussion 
The disubstituted piperazines of structure similar to GBR 12935 (Figure i) 
are a class of compounds which exhibit high affinity (KD=2-3 nM for [3H]GBR 
12935) for the dopamine uptake system and good selectivity for the dopamine 
system relative to other monoamine uptake systems (Ii). These characteristics 
make this class of compounds m~Jre appealing as candidates for carbon-ll or 
fluorinel8 labeling for PET studies than nomifensine or mazindol, drugs which 
are actually better antagonists of norepinephrine than dopamine uptake and have 
lower affinities in vitro for the dopamine uptake system (nomifensine KD=230 
nM, mazindol KD=I8 nM (12)). In addition, substitution of the aromatic rings 
of GBR 12935 with one or more ~luorines was known to produce derivatives with 
similar affinities and selectivities to that of GBR 12935 (ii). 
The in vivo behavior of [18F]GBR 13119 in rat brain is consistent with in 
vitro stE~ies with [3H]GBR 12935 (13,14) and a single in vivo study using 
[3H]GBR 12783 (l,2-(diphenylmethoxy)ethyl-4-(3-phenyl-2-propenyl)-piperazine) 
(15). Retention of radioactivity is highest in the striatum (Table I), with 
radioactivity in cerebral cortex and cerebellum steadily decreasing with time. 
The striatum-to-cerebellum ratio reaches a maximum of 3 at 90 minutes, similar 
to the ratio obtained in vivo with [3H]GBR 12783 at 60 minutes. Pharmacological 
blocking studies (Tables II and III) are consistent with radiotracer binding to 
the dopamine uptake system in vivo, and not to dopamine receptors. Uptake into 
the striatum is completely blocked by a pharmacological dose (8 mg/kg) of 
mazindol or nomifensine: cortex and cerebell~n are unaffected, suggesting 
uptake in those brain regions is largely non-specific. Striatum-to-cerebellum 
ratios remain unchanged by pretreatment with the dopamine receptor antagonists 
spiperone (D 2) and flupenthixol (DI). The dose of spiperone utilized is suffi- 
cient to effectively block [18F]spiperone uptake in rat striatum (16). Equi- 
valent doses (300 ug/kg) of nomifensine or mazindol only partially block the 
striatal uptake and retention of [18F]GBR 13119: in this study the decrease in 
striatum/cerebellum ratio was not as significant. A similar decrease in stria- 
tl~ radioactivity levels (but not str/cer ratio) was observed in the in vivo 
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dose-response study of [3H]GBR 12783 (15). 
In one published in vitro study of [3H]GBR 12935, Andersen proposes two 
separate binding sites for this radioligand (14). The first is the classical 
dopamine uptake system, which could be blocked by drugs such as mazindol and 
nomifensine. The second site proposed was a high affinity, uniformly distri- 
buted binding of disubstituted piperazines, which could be blocked in vitro 
with flupenthixol and piflutixol. In this study, it was not possible to dis- 
tinguish if the binding in non-target tissue (cerebellum) was due to binding to 
this purported piperazine binding site, or was simply non-specific binding as 
observed with ,,any other lipophilic radiotracers (3,4,17). 
[18F]GBR 13119 would thus appear to be a good candidate for further evalua- 
tion as a marker for the presynaptic dopamine uptake system. Brain uptake, 
regional selectivity, and pharmacological selectivity are all consistent with 
successful application in in vivo PET imaging. Non-specific binding in brain 
tissue is high, reflective of the lipophilic nature of this class of compounds. 
Determination of kinetic parameters (association and dissociation rates) and 
Bma x values will most likely require mathematical modeling of tissue-activity 
curves obtained in PET studies (17). The studies reported here are, of course, 
only the first steps in the development and validation of a radiopharmaceutical 
for PET studies in humans. Questions of brain uptake and selectivity in pri- 
mates (possible species differences), confounding aspects of radiotracer meta- 
bolism, difficulties in quantitative estimation of relevant bioche[~ical para- 
meters, and radiation dosimetry problems all remain unanswered. Successful 
development of a marker for the dopamine uptake system would be of great poten- 
tial in the study of degenerative neurological diseases, such as Parkinson's 
disease: decreased binding of [3H]GBR 12935 in vitro to caudate nucleus of 
Parkinson's patients (post-mortem) has been recently repgrted (18). Although 
others have cautioned, appropriately, with extending in vitro results to in 
vivo situations (19,20), such results are clearly an impetus for further 
evaluation of [18F]GBR 13119. 
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